Capital World Investors
SPRY icon

Capital World Investors’s ARS Pharmaceuticals SPRY Stock Holding History

Capital World Investors’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.1M Buy
+2,754,931
New +$23.7M ﹤0.01% 551

Other funds holding SPRY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
PCML
Pavaki Capital Management LLC Pueblo, Colorado $287M AUM

Capital World Investors's SPRY Position: Q2 2026 in Review

Capital World Investors opened a new position in ARS Pharmaceuticals (SPRY) in Q2 2026: 2,754,931 shares worth $22.1M. The stake represents ﹤0.01% of the portfolio and ranks #551 among its holdings.

109 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Capital World Investors held 2,754,931 shares of ARS Pharmaceuticals worth $22.1M as of Q2 2026.
  • ARS Pharmaceuticals was a new Capital World Investors position in Q2 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of Capital World Investors's portfolio in Q2 2026, its #551 holding.
  • 109 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Capital World Investors's 13F filing for Q2 2026, filed 12 Aug 2026.